Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

https://www.ajconline.org/article/S0002-9149(20)30861-4/fulltext
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).

Nelson AJ, Navar A, Mulder H, Wojdyla D, Philip S, Granowitz C, Peterson ED, Pagidipati NJ. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial). Am J Cardiol. 2020; epub ahead of print.

Pagidipati N, Navar A, Mulder H, Wojdyla DM, Philip S, Granowitz CB. Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trialDiabetes. 2019;68(suppl 1):1472P.

http://diabetes.diabetesjournals.org/content/68/Supplement_1/1472-P

Gitt AK. Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS. EMJ Cardiol. 2019;7:61-62.

https://emj.emg-health.com/wp-content/uploads/sites/2/2019/10/Icosapent-Ethyl-for-the-Prevention-of-Cardiovascular-Events.pdf

In Chronological Order

 

Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgrad Med. 2019; epub ahead of print. https://www.tandfonline.com/doi/full/10.1080/00325481.2019.1643633

https://www.ncbi.nlm.nih.gov/pubmed/31306043

Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. Generalizability of the REDUCE-IT trial in patients with stable coronary artery diseaseJ Am Coll Cardiol. 2019;73:1362-1364.
https://www.ncbi.nlm.nih.gov/pubmed/30819552

https://www.sciencedirect.com/science/article/pii/S0735109719302736?via%3Dihub=

Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL cholesterolDiabetes Obes Metab. 2019;21:366-371.
https://www.ncbi.nlm.nih.gov/pubmed/30225881

https://onlinelibrary.wiley.com/doi/full/10.1111/dom.13537

Borow KM, Mason RP, Vijayaraghavan K. Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: a review. Cardiorenal Med. 2018;8:18-30.
Free:

https://www.karger.com/Article/FullText/479391
Majithia A, Bhatt DL, Friedman AN, et al. Benefits of icosapent ethyl across a range of baseline renal function in patients with established cardiovascular disease or diabetes: results of REDUCE-IT RENAL [abstract FR-OR18]. J Am Soc Nephrol. 2020;31(suppl):21. https://www.asn-online.org/education/kidneyweek/archives/KW20Abstracts.pdf
American Society of Nephrology
Leatherman S, Ferguson RE, Hau C, et al. Increased residual cardiovascular risk in US veterans with moderately elevated baseline triglycerides, well-controlled LDL cholesterol levels on statins, and decreased renal function [abstract PO2067]. J Am Soc Nephrol. 2020;31(suppl):634-5. https://www.asn-online.org/education/kidneyweek/archives/KW20Abstracts.pdf
Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl: insights from REDUCE-IT REVASC.

American Society for Preventive Cardiology
Peterson BE, Bhatt DL, Steg G, et al. Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl:  insights from REDUCE-IT REVASC. Presented at the American Society for Preventive Cardiology 2020 annual meeting (virtual).

European Association for the Study of Diabetes
Bhatt DL, Brinton E, Miller M, et al. Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES [abstract 627]. Presented at the European Association for the Study of Diabetes meeting, September 21-25, 2020 (virtual). Diabetologia. 2020;63(1 suppl):303. https://upload.easd.org/download/EASD2020/Abstract%20Volume%2056th%20EASD%20Annual%20Meeting.pdf

Brinton EA, Ballantyne CM, Guyton JR, Philip S, Doyle RT Jr., Juliano RA, Mosca L. Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis. J Womens Health (Larchmt). 2018;27:1170-6.
https://www.liebertpub.com/doi/10.1089/jwh.2017.6757

https://www.ncbi.nlm.nih.gov/pubmed/29583081
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100.
Free:
http://www.cardiab.com/content/pdf/1475-2840-12-100.pdf

Amarin Corporation